» Articles » PMID: 34140469

BNT162b2 Vaccine Uptake and Effectiveness in UK Healthcare Workers - a Single Centre Cohort Study

Overview
Journal Nat Commun
Specialty Biology
Date 2021 Jun 18
PMID 34140469
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

In this single centre cohort study we assessed BNT162B2 vaccine uptake and effectiveness among UK healthcare workers (HCWs) during a time of high community COVID-19 prevalence. Early uptake among HCWs was 62.3% (1409/2260), however there were significant differences in uptake between age groups, ethnic origins, and job roles. Uptake increased to 72.9% after a vaccine hesitancy working group implemented specific measures. In the 42 days after vaccination, 49 new cases of COVID-19 were identified, of which 7 (14.3%) occurred in HCWs who were beyond 10 days of vaccination. Kaplan-Meier curves for partially vaccinated and unvaccinated groups were congruent until day 14 and continued to diverge up to 42 days. Cox regression analysis showed a 70.0% (95%CI 6.0-91.0; p=0.04) risk reduction for COVID-19 infection in partially vaccinated HCWs. Here we report early vaccination rates among HCWs are generally high although uptake is lower in certain groups. It is possible to improve vaccine uptake and efforts should focus on this, however, significant resource is required. The BNT162B2 vaccine is effective from 14 days post-vaccination in a frontline clinical setting and protection continues beyond 21 days post 1st dose without a 2nd dose, being given.

Citing Articles

Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses.

Padilla-Borquez D, Matuz-Flores M, Hernandez-Bello J, Rosas-Rodriguez J, Turrubiates-Hernandez F, Garcia-Arellano S Hum Vaccin Immunother. 2024; 20(1):2394265.

PMID: 39246041 PMC: 11385164. DOI: 10.1080/21645515.2024.2394265.


COVID-19 vaccine uptake among Ontario physicians: a descriptive population-based retrospective cohort study.

Liu C, Jeyakumar N, McArthur E, Sontrop J, Myran D, Schwartz K BMJ Open. 2024; 14(6):e080461.

PMID: 38858148 PMC: 11168153. DOI: 10.1136/bmjopen-2023-080461.


Consequences of COVID-19 Vaccine Hesitancy Among Healthcare Providers During the First 10 Months of Vaccine Availability: Scoping Review.

Wilpstra C, Morrell S, Mirza N, Ralph J Can J Nurs Res. 2024; 56(3):204-224.

PMID: 38693882 PMC: 11308270. DOI: 10.1177/08445621241251711.


Sociodemographic and socioeconomic disparities in COVID-19 vaccine uptake in Belgium: a nationwide record linkage study.

Cavillot L, van Loenhout J, Devleesschauwer B, Wyndham-Thomas C, Van Oyen H, Ghattas J J Epidemiol Community Health. 2023; .

PMID: 38148149 PMC: 11045363. DOI: 10.1136/jech-2023-220751.


Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review.

Reynolds L, Dewey C, Asfour G, Little M Front Public Health. 2023; 11:1229716.

PMID: 37942238 PMC: 10628441. DOI: 10.3389/fpubh.2023.1229716.


References
1.
Hall V, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A . COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021; 397(10286):1725-1735. PMC: 8064668. DOI: 10.1016/S0140-6736(21)00790-X. View

2.
Pan D, Sze S, Minhas J, Bangash M, Pareek N, Divall P . The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine. 2020; 23:100404. PMC: 7267805. DOI: 10.1016/j.eclinm.2020.100404. View

3.
Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

4.
Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020; 396(10267):1979-1993. PMC: 7674972. DOI: 10.1016/S0140-6736(20)32466-1. View

5.
Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View